IMCR immunocore.com: Enterprise Value to EBITDA Ratio

Graphic logo of Immunocore (IMCR)

Immunocore Holdings plc (IMCR) maintains a powerful market barrier through its patent-protected melanoma treatment platform. The company's EV/EBITDA ratio on the financial timeline confirms investment stability, where 0.00 represents the latest metric reading. High authority in immuno-oncology is coupled with a dependence on clinical trial outcomes and the scaling of unique drug production, which will determine the brand's future success.

Immunocore PLC - IMCR Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

Summary analytical data breakdowns for Immunocore PLC (IMCR)

- stock price and consensus target price:
Fundamental company analysis:IMCR (Immunocore)
Original product of Immunocore Holdings

Immunocore Holdings plc (IMCR) maintains pricing power in the rare oncology segment, ensuring high margins that are critical for servicing its debt load. By analyzing the EV/EBITDA multiple trend on the GURU.Markets platform, an investor assesses the ratio of total enterprise value to operating profit, determining capital management efficiency and the level of market confidence in the company's stability amid high tax liabilities.

Competitor analysis for Immunocore Holdings plc

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Janux Therapeutics, Inc. (JANX) - Company Value to EBITDA|RCUS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ZYME (Zymeworks)|TNGX: EV/EBITDA Multiple|IOVA - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization immatics.com|Enterprise Value to EBITDA Ratio xencor.com (XNCR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics Inc (CMPX)|Enterprise Value to EBITDA Ratio Replimune Corp REPL|Lyell - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma S.A IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen) - Enterprise Value to Operating Income Before Depreciation|IO Biotech Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Sutro Bio (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma Inc.)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Bio|Liminatus Pharma (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics NV - Business Value to Operating Income Before Depreciation|NXTC (nextcure.com) - EV/EBITDA Multiple|EV/EBITDA Multiple leaptx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics